350 related articles for article (PubMed ID: 7807971)
1. Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study.
Okon E; Pouliquen D; Okon P; Kovaleva ZV; Stepanova TP; Lavit SG; Kudryavtsev BN; Jallet P
Lab Invest; 1994 Dec; 71(6):895-903. PubMed ID: 7807971
[TBL] [Abstract][Full Text] [Related]
2. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging.
Briley-Saebo K; Bjørnerud A; Grant D; Ahlstrom H; Berg T; Kindberg GM
Cell Tissue Res; 2004 Jun; 316(3):315-23. PubMed ID: 15103550
[TBL] [Abstract][Full Text] [Related]
3. [Toxicity of magnetite-dextran particles: morphological study].
Okon EE; Pulikan D; Pereverzev AE; Kudriavtsev BN; Zhale P
Tsitologiia; 2000; 42(4):358-66. PubMed ID: 10849930
[TBL] [Abstract][Full Text] [Related]
4. Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism.
Pouliquen D; Le Jeune JJ; Perdrisot R; Ermias A; Jallet P
Magn Reson Imaging; 1991; 9(3):275-83. PubMed ID: 1881245
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution of ultrasmall iron oxide particles in the rat liver.
Van Beers BE; Sempoux C; Materne R; Delos M; Smith AM
J Magn Reson Imaging; 2001 Apr; 13(4):594-9. PubMed ID: 11276104
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat.
Majumdar S; Zoghbi SS; Gore JC
Invest Radiol; 1990 Jul; 25(7):771-7. PubMed ID: 2391194
[TBL] [Abstract][Full Text] [Related]
7. Long-term imaging effects in rat liver after a single injection of an iron oxide nanoparticle based MR contrast agent.
Briley-Saebø K; Hustvedt SO; Haldorsen A; Bjørnerud A
J Magn Reson Imaging; 2004 Oct; 20(4):622-31. PubMed ID: 15390223
[TBL] [Abstract][Full Text] [Related]
8. Dextran magnetite as a liver contrast agent.
Magin RL; Bacic G; Niesman MR; Alameda JC; Wright SM; Swartz HM
Magn Reson Med; 1991 Jul; 20(1):1-16. PubMed ID: 1943651
[TBL] [Abstract][Full Text] [Related]
9. Liver-directed superparamagnetic iron oxide: quantitation of T2 relaxation effects.
Pouliquen D; Lucet I; Chouly C; Perdrisot R; Le Jeune JJ; Jallet P
Magn Reson Imaging; 1993; 11(2):219-28. PubMed ID: 8455432
[TBL] [Abstract][Full Text] [Related]
10. USPIO (Ferumoxtran-10)-enhanced MRI to visualize reticuloendothelial system cells in neonatal rats: feasibility and biodistribution study.
Azoulay R; Olivier P; Baud O; Verney C; Santus R; Robert P; Gressens P; Sebag G
J Magn Reson Imaging; 2008 Oct; 28(4):1046-52. PubMed ID: 18821607
[TBL] [Abstract][Full Text] [Related]
11. Clearance of iron oxide particles in rat liver: effect of hydrated particle size and coating material on liver metabolism.
Briley-Saebo KC; Johansson LO; Hustvedt SO; Haldorsen AG; Bjørnerud A; Fayad ZA; Ahlstrom HK
Invest Radiol; 2006 Jul; 41(7):560-71. PubMed ID: 16772849
[TBL] [Abstract][Full Text] [Related]
12. Long circulating superparamagnetic particles with high T2 relaxivity.
Pochon S; Hyacinthe R; Terrettaz J; Robert F; Schneider M; Tournier H
Acta Radiol Suppl; 1997; 412():69-72. PubMed ID: 9240083
[TBL] [Abstract][Full Text] [Related]
13. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10.
Raynal I; Prigent P; Peyramaure S; Najid A; Rebuzzi C; Corot C
Invest Radiol; 2004 Jan; 39(1):56-63. PubMed ID: 14701989
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10.
Islam T; Wolf G
Cancer Biomark; 2009; 5(2):69-73. PubMed ID: 19414923
[TBL] [Abstract][Full Text] [Related]
15. Histochemical detection of ultrasmall superparamagnetic iron oxide (USPIO) contrast medium uptake in experimental brain ischemia.
Schroeter M; Saleh A; Wiedermann D; Hoehn M; Jander S
Magn Reson Med; 2004 Aug; 52(2):403-6. PubMed ID: 15282824
[TBL] [Abstract][Full Text] [Related]
16. MRI detection of macrophages labeled using micrometer-sized iron oxide particles.
Williams JB; Ye Q; Hitchens TK; Kaufman CL; Ho C
J Magn Reson Imaging; 2007 Jun; 25(6):1210-8. PubMed ID: 17520727
[TBL] [Abstract][Full Text] [Related]
17. Superparamagnetic iron oxide: pharmacokinetics and toxicity.
Weissleder R; Stark DD; Engelstad BL; Bacon BR; Compton CC; White DL; Jacobs P; Lewis J
AJR Am J Roentgenol; 1989 Jan; 152(1):167-73. PubMed ID: 2783272
[TBL] [Abstract][Full Text] [Related]
18. Relaxation effects of clustered particles.
Tanimoto A; Oshio K; Suematsu M; Pouliquen D; Stark DD
J Magn Reson Imaging; 2001 Jul; 14(1):72-7. PubMed ID: 11436217
[TBL] [Abstract][Full Text] [Related]
19. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling.
Yancy AD; Olzinski AR; Hu TC; Lenhard SC; Aravindhan K; Gruver SM; Jacobs PM; Willette RN; Jucker BM
J Magn Reson Imaging; 2005 Apr; 21(4):432-42. PubMed ID: 15779033
[TBL] [Abstract][Full Text] [Related]
20. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model.
Moore A; Marecos E; Bogdanov A; Weissleder R
Radiology; 2000 Feb; 214(2):568-74. PubMed ID: 10671613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
